NASDAQ : HURA
TuHURA Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 122.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 8.15M | 7.58M | 3.87M | 4.14M | 2.01M |
| Research & Development | 22.88M | 20.53M | 13.34M | 9.40M | 7.93M |
| Operating Expenses | 31.02M | 28.12M | 17.21M | 13.55M | 9.93M |
| Operating Income | -31.02M | -28.12M | -17.21M | -13.55M | -9.93M |
| Interest Expense | -1.12M | -625.28K | -4.14M | -18.69K | |
| Interest & Investment Income | 35.56K | 136.23K | 361.63K | 89.67K | 57.35K |
| Other Non Operating Income (Expenses) | 138.30K | 713.51K | -256.14K | 42.47K | 214.92K |
| EBT Excluding Unusual Items | -31.97M | -27.89M | -21.24M | -13.43M | -9.66M |
| Merger & Restructuring Charges | -173.59K | -3.68M | -440.34K | ||
| Gain (Loss) on Sale of Investments | 1.59M | 1.59M | |||
| Other Unusual Items | -71.44K | -71.44K | 334.44K | 294.07K | |
| Pretax Income | -30.62M | -30.05M | -21.68M | -29.32M | -9.37M |
| Net Income | -30.62M | -30.05M | -21.68M | -29.32M | -9.37M |
| Preferred Dividends & Other Adjustments | 8.36K | 8.36K | 967.27K | ||
| Net Income to Common | -30.63M | -30.06M | -22.65M | -29.32M | -9.37M |
| Shares Outstanding (Basic) | 56.43M | 47.93M | 18.66M | 11.89M | |
| Shares Outstanding (Diluted) | 56.43M | 47.93M | 18.66M | 11.89M | |
| EPS (Basic) | -0.54 | -0.63 | -1.21 | -2.47 | |
| EPS (Diluted) | -0.54 | -0.63 | -1.21 | -2.47 | |
| Free Cash Flow | -29.90M | -27.71M | -14.79M | -13.25M | -7.54M |
| Free Cash Flow Per Share | -0.53 | -0.58 | -0.79 | -1.11 | |
| EBITDA | -30.93M | -28.05M | -17.09M | -13.37M | -9.56M |
| D&A For EBITDA | 95.41K | 71.27K | 116.71K | 177.38K | 373.09K |
| EBIT | -31.02M | -28.12M | -17.21M | -13.55M | -9.93M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 995.98K | 3.62M | 12.66M | 3.67M | 14.25M |
| Cash & Short-Term Investments | 995.98K | 3.62M | 12.66M | 3.67M | 14.25M |
| Other Receivables | 304.22K | 667.66K | 642.36K | 334.44K | |
| Receivables | 304.22K | 667.66K | 642.36K | 334.44K | 101.24K |
| Other Current Assets | 217.90K | 333.53K | 6.31M | 159.33K | 390.53K |
| Total Current Assets | 1.66M | 4.62M | 19.61M | 4.16M | 14.74M |
| Property, Plant & Equipment | 745.67K | 685.17K | 322.53K | 202.99K | 418.55K |
| Goodwill | 10.74M | 10.74M | |||
| Long-Term Deferred Charges | 11.28M | 11.28M | |||
| Other Long-Term Assets | 7.33M | 33.77K | 33.77K | 33.77K | |
| Total Assets | 31.75M | 27.35M | 19.97M | 4.36M | 15.20M |
| Accounts Payable | 3.08M | 3.77M | 3.15M | 1.87M | 1.92M |
| Accrued Expenses | 792.50K | 1.75M | 2.02M | 1.57M | 838.68K |
| Short-Term Debt | 5.17M | 197.35K | |||
| Current Portion of Leases | 214.18K | 199.04K | 159.84K | 20.82K | 117.48K |
| Other Current Liabilities | 137.00K | ||||
| Total Current Liabilities | 9.26M | 5.92M | 5.33M | 3.60M | 2.87M |
| Long-Term Debt | 3.60M | 2.32M | |||
| Long-Term Leases | 192.85K | 303.63K | 42.70K | 20.74K | |
| Long-Term Deferred Tax Liabilities | 197.92K | 197.92K | |||
| Total Liabilities | 13.25M | 6.42M | 5.37M | 5.92M | 2.89M |
| Common Stock | 63.68K | 59.34K | 42.32K | 12.17K | 4.53K |
| Additional Paid-In Capital | 176.11M | 161.78M | 125.40M | 86.89M | 71.45M |
| Retained Earnings | -157.95M | -141.18M | -111.12M | -88.47M | -59.16M |
| Total Common Equity | 18.22M | 20.65M | 14.32M | -1.58M | 12.30M |
| Shareholders' Equity | 18.50M | 20.93M | 14.59M | -1.56M | 12.30M |
| Total Liabilities & Equity | 31.75M | 27.35M | 19.97M | 4.36M | 15.20M |
| Total Debt | 9.18M | 700.02K | 202.54K | 2.34M | 138.22K |
| Net Cash (Debt) | -8.18M | 2.92M | 12.45M | 1.32M | 14.11M |
| Net Cash Per Share | -0.15 | 0.06 | 0.67 | 0.11 | |
| Filing Date Shares Outstanding | 63.73M | 63.58M | 43.68M | 68.01M | |
| Total Common Shares Outstanding | 63.68M | 59.34M | 42.32M | 68.01M | |
| Working Capital | -7.60M | -1.30M | 14.28M | 562.42K | 11.87M |
| Book Value Per Share | 0.29 | 0.35 | 0.34 | -0.02 | |
| Tangible Book Value | 7.48M | 9.92M | 14.32M | -1.58M | 12.30M |
| Tangible Book Value Per Share | 0.12 | 0.17 | 0.34 | -0.02 | |
| Machinery | 2.03M | 1.84M | 1.59M | 1.54M | 1.50M |
| Leasehold Improvements | 544.63K | 544.63K | 544.63K | 544.63K | 544.63K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -30.62M | -30.05M | -21.68M | -29.32M | -9.37M |
| Depreciation & Amortization | 95.41K | 71.27K | 116.71K | 177.38K | 373.09K |
| Other Amortization | 776.71K | 481.42K | 1.28M | 5.12K | |
| Asset Writedown & Restructuring Costs | 16.22M | ||||
| Loss (Gain) From Sale of Investments | -1.59M | -1.59M | |||
| Stock-Based Compensation | 8.53M | 6.42M | 1.96M | 478.89K | 218.28K |
| Other Operating Activities | 185.02K | 185.02K | 313.77K | -294.07K | |
| Change in Accounts Payable | -7.72M | -3.76M | 3.64M | 337.75K | 1.85M |
| Change in Other Net Operating Assets | 659.89K | 612.52K | -358.32K | 149.18K | -286.51K |
| Operating Cash Flow | -29.69M | -27.63M | -14.73M | -11.95M | -7.51M |
| Capital Expenditures | -213.67K | -76.08K | -57.91K | -1.30M | -36.28K |
| Cash Acquisitions | -1.26M | -5.99M | |||
| Investing Cash Flow | -213.67K | -1.34M | -6.05M | -1.30M | -36.28K |
| Short-Term Debt Issued | 3.00M | ||||
| Long-Term Debt Issued | 28.57M | 2.69M | |||
| Total Debt Issued | 6.60M | 3.00M | 28.57M | 2.69M | |
| Short-Term Debt Repaid | -2.33M | ||||
| Long-Term Debt Repaid | -54.31K | -350.00K | |||
| Lease Payments | -54.31K | -54.31K | |||
| Total Debt Repaid | -2.60M | -2.38M | -350.00K | ||
| Net Debt Issued (Repaid) | 4.00M | 616.98K | 28.57M | 2.69M | -350.00K |
| Issuance of Common Stock | 20.20M | 21.92M | 7.05M | ||
| Repurchase of Common Stock | -24.75K | ||||
| Preferred Dividends Paid | -8.36K | -8.36K | |||
| Dividends Paid | -8.36K | -8.36K | |||
| Other Financing Activities | -1.80M | -2.61M | -5.84M | ||
| Financing Cash Flow | 22.39M | 19.93M | 29.77M | 2.66M | 16.25M |
| Net Cash Flow | -7.52M | -9.04M | 8.99M | -10.59M | 8.71M |
| Free Cash Flow | -29.90M | -27.71M | -14.79M | -13.25M | -7.54M |
| Free Cash Flow Per Share | -0.53 | -0.58 | -0.79 | -1.11 | |
| Levered Free Cash Flow | -18.28M | -4.76M | -14.91M | -8.29M | |
| Unlevered Free Cash Flow | -18.35M | -4.85M | -13.60M | -8.29M | |
| Free Cash Flow After Leases | -29.96M | -27.76M | -14.79M | -13.25M | -7.54M |
| Cash Interest Paid | 87.34K | 59.36K | |||
| Change in Working Capital | -7.06M | -3.15M | 3.29M | 486.92K | 1.56M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 122.99M | 45.95M | 172.94M | ||
| Enterprise Value | 131.18M | 44.23M | 177.96M | ||
| Last Close Price | 1.93 | 0.76 | 4.09 | ||
| PB Ratio | 6.75 | 2.19 | 11.85 | ||
| P/TBV Ratio | 16.43 | 4.63 | 12.08 | ||
| Debt / Equity Ratio | 0.50 | 0.03 | 0.01 | -1.50 | 0.01 |
| Net Debt / Equity Ratio | 0.44 | -0.14 | -0.85 | 0.85 | -1.15 |
| Net Debt / EBITDA Ratio | -0.27 | 0.10 | 0.73 | 0.10 | 1.48 |
| Net Debt / FCF Ratio | -0.27 | 0.10 | 0.84 | 0.10 | 1.87 |
| Quick Ratio | 0.14 | 0.72 | 2.50 | 1.11 | 4.96 |
| Current Ratio | 0.18 | 0.78 | 3.68 | 1.16 | 5.13 |
| Return on Equity (ROE) | -161.39% | -169.18% | -332.67% | -545.67% | |
| Return on Assets (ROA) | -58.43% | -74.27% | -88.42% | -86.58% | |
| Return on Capital Employed (ROCE) | -137.90% | -131.20% | -117.60% | -1,769.90% | -80.60% |
| Earnings Yield | -28.12% | -65.41% | -12.54% | ||
| FCF Yield | -24.31% | -60.30% | -8.55% | ||
| Buyback Yield / Dilution | -60.94% | -156.81% | -56.97% |